Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.38 |
| ▸ | HTR2A | P28223 | 13/20 | 0.38 |
| ▸ | HTR2B | P41595 | 8/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000307 | 0.89 | HTR2C (0.37) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL6000146 | 0.87 | SLC6A4 (0.52) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5998743 | 0.84 | MTNR1A (0.37) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL5502055 | 0.79 | TAAR1 (0.44) | HTR2CHTR2AHTR2BSLC6A4KCNH2 | |
| SCHEMBL5501819 | 0.78 | SOS1 (0.36) | HTR2CHTR2AHTR2BSLC6A4KCNH2 | |
| SCHEMBL6000301 | 0.77 | SLC6A4 (0.53) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5503523 | 0.75 | TAAR1 (0.43) | HTR2CHTR2AHTR2BSLC6A4KCNH2 | |
| SCHEMBL5502595 | 0.75 | TAAR1 (0.47) | HTR2CHTR2AHTR2BSLC6A4KCNH2 | |
| SCHEMBL5501642 | 0.73 | TAAR1 (0.51) | HTR2CHTR2AHTR2BTAAR1ADRA1A | |
| SCHEMBL5998739 | 0.72 | SLC6A4 (0.53) | HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | HTR2C 2/4885HTR2A 7/4885HTR2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.